Acute Kidney Injury Market

Acute Kidney Injury Market Size Survey Report – In a Glance

As per the survey report on global Acute kidney injury market, the market is projected to foresee a CAGR of 8.4% between 2024-2033, and further generate a market size of USD 3.7 billion revenue by the end of 2033. In the year 2024, the market size was valued at USD 1.7 billion revenue.

• The global acute kidney injury market is projected to grow on account of the increasing incidence of acute kidney injury.
• In Japan, the acute kidney injury market growth can be attributed to the booming older population.
• KDMI analyst’s growth analysis foresees insufficient awareness and education to challenge the market growth.
• North America, having the highest market share in the acute kidney injury market, is projected to dominate the global market.

Acute Kidney Injury Market Analysis

Acute kidney injury (AKI) is a sudden impairment of kidney function, leading to decreased urine output and causing accumulation of toxins in the blood. It is commonly caused by infections, dehydration, toxic wastes, or poor blood supply. The increasing incidence of acute kidney injury has been a key driver behind the growth of the AKI market. More than 2 million people around the world depend on dialysis or a kidney transplant to sustain their lives. This surge drives the need for medical diagnostics, dialysis, and drugs, hence, stimulating the market expansion worldwide. Renibus Therapeutics, Ocelot Bio, Alexion Pharmaceuticals, are some of the significant parties in the global market for Acute kidney injury.

Analyst’s Observation on Japan Acute Kidney Injury Market Survey

Compared to other developing nations, Japan has a large number of older citizens. This spike is attributed to various factors namely, improved medical infrastructure, favourable insurance policies, and progress in the healthcare system. However, the booming older population is responsible for the acute kidney injury market growth. Studies suggest that older people are at greater risk of acute kidney injury (AKI). It is also found that the country has an escalated number of chronic kidney disease (CKD) patients. Therefore, with the growing aging population in the country, AKI cases also increase, fueling the demand for AKI medications and accelerating the market growth. Mitsui Chemicals, AstraZeneca, Asahi Kasei Medical Co Ltd, are some of the significant parties in the market for Acute kidney injury in Japan.

Acute Kidney Injury Market Growth Drivers and Challenges

Growth Drivers

Mounting load of chronic conditions:

Chronic diseases have become a dominant issue for global healthcare systems. The surge in lifestyle-linked chronic conditions, specifically hypertension and diabetes, are the major contributors to acute kidney injury (AKI) and are the key factors of market growth. As diabetes and hypertension remain uncontrolled or unmanaged for a long period, the risk of developing chronic kidney disease and last-stage renal failure has escalated too. According to a recent study, the count of adults affected by diabetes has crossed 800 million. Autoimmune disorders and glomerulonephritis are also associated with kidney damage. Besides these, an aging global population is prone to multiple health issues which further complicate the chronic disease landscape. Therefore, as people grapple with long-term metabolic and cardiovascular disorders, the likelihood of acute kidney issues also increases, steering the AKI market forward.

Progress in medical diagnostics:

The current era of medical progress has transformed healthcare remarkably. This is particularly noticeable in the early diagnosis of acute kidney injury (AKI). Cutting-edge diagnostic tools enable early detection of AKI and timely treatments that can prevent it from worsening to severe stages necessitating dialysis or kidney transplantation. For instance, artificial intelligence (AI) emerged as a powerful tool for progressing chronic kidney disease (CKD), providing greater accuracy than traditional methods. Hence, progress in medical diagnostics aid in faster identification of AKI, allowing timely medical care and reduced complications. Furthermore, advanced biomarkers, AI-assisted tools, and advanced imaging techniques improve accuracy, spurring the AKI industry. As early diagnosis becomes a priority, the AKI market grows, powered by technological advancements and better patient prognosis.

Restraints

Insufficient awareness and education:

Limited knowledge and education impede the acute kidney injury (AKI) market by causing late diagnosis, curbing patient access to medical care, poor compliance with clinical protocols, and delaying advanced treatment options. This gap in knowledge between patient and healthcare providers limit the AKI market development because of the mismanagement and weaker demand for new technologies.

Compliance challenges:

Policy restrictions challenge the acute kidney injury (AKI) market by increasing legal burdens, restricting the introduction of new treatments, raising financial pressures, and driving up costs. Tighter rules block new solutions and innovations, limiting access and adoption of new treatments. Medical practitioners face difficulties in meeting standards, impacting patient outcomes and stifling market development.

Acute Kidney Injury Market Segmentation

Our experts at KD Market Insights have segmented the global acute kidney injury market research report as:

Acute Kidney Injury Market Regional Synopsis

North America leads the direction in the acute kidney injury (AKI) market and is majorly driven by its significant increase in pharmaceutical research and development activities. Besides that, the increasing AKI patient pool, the progressive healthcare systems, the presence of major market players, increased awareness among the public, and favorable regulatory policies in Canada and the United States further drive the market within the region. The United States holds the largest share of the regional acute kidney injury (AKI) market within the given period because of the presence of pharmaceutical companies, growing advancements in treatment options, and increasing adoption of innovative treatments along with a promising drug development pipeline in the country. However, as per statistics, the total R&D expenditures have hit a value of almost US$ 1.7 trillion.

Asia-Pacific (APAC) is encountering the quickest market surge during the forecasted period. The region functions as a central point for pharmaceutical businesses. This is mainly due to expansive distribution channels and trade connections. Furthermore, the market is also driven by the growing prevalence of chronic diseases, increasing use of generic drugs, economic growth, consumer demands, and progressing healthcare framework. India is also upgrading the acute kidney injury (AKI) market due to its massive population, surging cases of chronic diseases, rising public awareness, greater healthcare investments and strengthening healthcare systems. In addition to that, Japan’s economic progress is likely to expand at a rate beyond its expected growth capacity. China is also contributing a significant part to the regional market. It has implemented the world’s largest planned urban transformation program, thereby, promoting healthcare development. Also, numerous medical research and drug developments have supported its overall healthcare framework and economic growth goals.

In Europe, several government organizations are supporting early detection, enhanced patient outcomes, increasing medical spending, and preventive measures for acute kidney injury (AKI) are mainly expected to drive market expansion in the coming future. Moreover, the UK is at the forefront of the development of the market in the region due to its increasingly improved diagnostics and strong healthcare policies. Various factors are responsible for the market evolution in the area such as the availability of cutting-edge therapies, growing public awareness about kidney disorders, and expanding availability of medical solutions.

As per our analysts at KD Market Insights, the following five players lead the North America Acute kidney injury market growth:

• Pfizer Inc.
• Medtronic plc
• GE Healthcare
• Novartis AG
• B. Braun Melsungen AG

Acute Kidney Injury Market Competitive Landscape

Some of the key players who top the global acute kidney injury market share:

• Angion Biomedica Corp.
• AM-Pharma
• Quark Pharmaceuticals Inc.
• Fresenius Medical Care AG & Co. KGaA.
• B. Braun Melsungen AG
• Asahi Kasei Medical Co. Ltd.
• LG Chem
• Pfizer Inc.
• AstraZeneca
• Novartis AG
• Sanofi
• Baxter International Inc.
• Medtronic plc
• GE Healthcare

1. Executive Summary
   1. Market Overview
   2. Key Findings
   3. Market Trends
   4. Market Outlook
2. Introduction
   1. Scope of the Report
   2. Research Methodology
   3. Definitions and Assumptions
   4. Acronyms and Abbreviations
3. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
   4. Challenges
4. Global Acute Kidney Injury Market
   1. Market Overview
   2. Market Size and Forecast
   3. Market Segmentation
      1. By Treatment
      2. By Type
      3. By Distribution channel
      4. By Region
5. Market Segmentation by Treatment
   1. 1. Therapy
      2. Drugs
6. Market Segmentation by Type
   1. 1. Pre-renal acute kidney injury
      2. Intrinsic renal acute kidney injury
      3. Post-renal acute kidney injury
7. Market Segmentation by Distribution channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

1. Regional Analysis
   1. North America
      1. United States
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
      2. Canada
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
      3. Mexico
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
   2. Europe
      1. United Kingdom
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
      2. Germany
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
      3. France
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
      4. Italy
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
      5. Spain
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
      6. Rest of Europe
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
   3. Asia Pacific
      1. China
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
      2. Japan
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
      3. India
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
      4. Australia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
         4. South Korea
         5. Market Size and Forecast
         6. Key Trends and Developments
         7. Market Analysis by Treatment, Type, and Distribution channel
      5. Rest of Asia Pacific
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
   4. Latin America
      1. Brazil
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
      2. Argentina
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
      3. Colombia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
      4. Rest of Latin America
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
   5. Middle East & Africa
      1. South Africa
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
      2. Saudi Arabia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
      3. UAE
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
      4. Rest of Middle East & Africa
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment, Type, and Distribution channel
2. Competitive Landscape
   1. Market Share Analysis
   2. Company Profiles
   3. B. Braun Melsungen AG
   4. Asahi Kasei Medical Co. Ltd.
   5. LG Chem
   6. Pfizer Inc.
   7. AstraZeneca
   8. Novartis AG
   9. Sanofi
   10. Baxter International Inc.
   11. Medtronic plc
   12. GE Healthcare
3. Strategic Recommendations
4. Appendix
   1. List of Tables
   2. List of Figures
5. References